Jump to content

Talk:Artivion

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Request Edits June 2023

[edit]

As the flags at the top of this page show, this article has several issues, which I’m going to try to address with this proposal. I work for WhiteHatWiki.com, a paid consultant to Artivion. Below are my suggestions to address these issues so the flag can be removed.

Edit request

1. The current Infobox contains a good deal of information that is unsourced, inaccurate, or out of date. I propose this replaced information: Infobox company | name = Artivion, Inc. | logo = | type = [[Public company|Public]] | traded_as = {{NYSE|AORT}}<br />[[List of S&P 600 companies|S&P 600]] component | company_slogan = | foundation = 1984<ref name=PBP87>{{cite news |title=Tissue frozen for transplant later |work=Atlanta Journal-Constitution |date=12 September 1987}}</ref><ref name=CNNMoney09>{{cite news |last1=Zouhali-Worrall |first1=Malika |title=CryoLife's near-death experience |url=https://money.cnn.com/2009/07/01/smallbusiness/cryolife_crisis_management.fsb/index.htm |access-date=13 March 2023 |work=CNN Money |date=6 July 2009}}</ref> | founder = Steven Anderson<ref name=PBP87 /><ref name=ABC15>{{cite news |title=CryoLife Founder and Chairman Steven Anderson retires |url=https://www.bizjournals.com/atlanta/news/2015/04/10/cryolife-founder-and-chairman-steven-anderson.html |access-date=13 March 2023 |work=Atlanta Business Chronicle |date=10 April 2015}}</ref> and Robert McNally<ref name=PBP87 /> | location = [[Kennesaw, Georgia]], United States<ref name=CNNMoney09 /> | key_people = Mat Packin, Chairman of the Board, President & CEO<ref name=BizJour14>{{cite news |last1=Grayson |first1=Katharine |title=Leader of Medtronic’s biggest business unit leaves for CEO job |url=https://www.bizjournals.com/twincities/blog/in_private/2014/07/medtronic-pat-mackin-leaves-for-cryolife.html |access-date=13 March 2023 |work=Minneapolis/St. Paul Business Journal |date=14 July 2014}}</ref> | num_employees = 1300 (2022)<ref>{{cite web |title=The 2022 Medtech Big 100: The world’s largest medical device companies |url=https://www.medicaldesignandoutsourcing.com/2022-big-100/ |publisher=Medical Design and Outsourcing |access-date=14 March 2023}}</ref> | industry = Medical Device<ref>{{cite news |title=Life Story: Dr. Ronald C. Elkins |url=https://www.oklahoman.com/obituaries/pokl0425973 |access-date=13 March 2023 |work=The Oklahoman |date=15 February 2023}}</ref> | revenue = $298,836,000 (2022)<ref>{{cite web |title=The 2022 Medtech Big 100: The world’s largest medical device companies |url=https://www.medicaldesignandoutsourcing.com/2022-big-100/ |publisher=Medical Design and Outsourcing |access-date=14 March 2023}}</ref> | operating profit = | products = Human tissues for transplant, surgical sealants, mechanical heart valves, stents and grafts<ref>{{cite news |title=Life Story: Dr. Ronald C. Elkins |url=https://www.oklahoman.com/obituaries/pokl0425973 |access-date=13 March 2023 |work=The Oklahoman |date=15 February 2023}}</ref> | homepage = {{URL|http://www.artivion.com}}


2. This article does not make clear that until 2022 Artivion was previously known as CryoLife. I propose adding the following new sentence to the end of the first paragraph of the article to clarify this:

In January 2022, the company – which had previously been known as CryoLife – changed its name to Artivion, Inc.[1]

3. The first sentence of the second paragraph (which begins with “Artivion, Inc. incorporated in 1984…”) is unsourced and contains claims that I was unable to verify with any WP:RS. I propose replacing it with a new paragraph that details the company’s foundation, and which is sourced to both a 1987 article in the Palm Beach Post and a 2009 CNN Money article:

Artivion was founded as CryoLife in Sarasota, Florida in 1984 by Steven Anderson and Robert McNally.[2] The company later moved from Sarasota to the Atlanta metropolitan area.[2] Anderson, who had previously been the head of marketing at a pacemaker company in Texas,[3] was appointed as the company’s president and CEO, while McNally became its vice president and chief clinical researcher.[2][3]

Here’s an excerpt from Palm Beach Post, which is not online:

The first few years have been busy for Steven Anderson and Robert mcNally, who founded CryoLife three years ago in Sarasota before moving it to the Atlanta area. Anderson, the president of the company, is a marketing expert. McNally, vice president, is the company’s chief clinical researcher.

4. The third sentence in the second paragraph of the present article is unsourced and contains jargon and promotional language. I suggest a two-sentence replacement based on a 2008 article in the Atlanta Journal-Constitution:

In February 2008, the FDA gave CryoLife approval for a new kind of heart valve, made from human tissue, which was the first to remove cells from the transplant tissue as opposed to only cleaning the tissue.[4] According to the FDA ruling, the new valve, called the CryoValve SynerGraft Pulmonary Valve, potentially had a lower risk of rejection than previous implants based on human tissue.[4]

Here’s an excerpt from the Atlanta Journal-Constitution article, which is behind a paywall:

The Food and Drug Administration approved a new type of CryoLife heart valve it said may lower the risk of rejection, the Kennesaw-based company said Thursday. The device will be the first heart valve made from human tissue that has had cells removed. Ordinarily, when human tissue is removed from a donor to make a heart valve it is cleaned to prevent infection, but it remains unchanged otherwise. The CryoValve SynerGraft Pulmonary Valve goes through an extra step to remove tissue cells, leaving a scaffoldlike valve, CryoLife said in a statement. The company added that the FDA said this process may lower the chance of triggering the body's immune system.

5. The fourth sentence in the second paragraph (which begins “Artivion's medical devices consist of…”) is unsourced. I suggest replacing that sentence with the following three reliably sourced paragraphs.

In 2000, CryoLife began offering a surgical adhesive called BioGlue used for sealing surgical lacerations under high pressure, such as in arteries.[3]

In January 2016, the company acquired On-X Life Technologies and its principal product, a mechanical heart valve called the On-X aortic valve replacement, for $130 million.[5]

CryoLife also used to produce a product called PerClot that removes water from blood and helps to aid the clotting process in bleeding tissues; PerClot was sold in July 2021 to Baxter International.[6]

6. Please delete the third paragraph of the present article. There is no sourcing for the entire paragraph, and most of it is simply off-topic and/or contains non-neutral language.

The paragraph starts as follows:

The company preserves small diameter human saphenous vein conduits (3mm to 6mm) for use in peripheral vascular reconstructions and coronary bypass surgery…

7. The current fourth paragraph is based on unreliable press releases and contains inaccurate information (e.g., it says that JOTEC was acquired for $225 million when in fact it was for €225 million, according to the German Schwarzwalder Bote paper). It’s also missing Artivion’s other main acquisition of Ascyrus Medical in 2020.

I propose the following replacement for that paragraph:

In October 2017, Artivion acquired JOTEC AG, a German-based developer of medical devices for aortic and peripheral vascular diseases, for €225 million.[7] In September 2020, the company acquired Ascyrus Medical.[8]

8. I believe the changes proposed above resolve the issues pointed out by the flag. So I’d request it be removed.

Thanks. W12SW77 (talk) 20:15, 28 June 2023 (UTC) W12SW77 (talk) 20:15, 28 June 2023 (UTC) [reply]

Edit request references

References

  1. ^ Kirsh, Danielle (18 January 2022). "CryoLife announces corporate rebrand, changes name to Artivion". MassDevice. Retrieved 13 March 2023.
  2. ^ a b c Cite error: The named reference PBP87 was invoked but never defined (see the help page).
  3. ^ a b c Cite error: The named reference CNNMoney09 was invoked but never defined (see the help page).
  4. ^ a b Hendrick, Bill (8 February 2008). "Kennesaw firm wins OK for heart valve: Risk of rejection may be lower for CryoLife device". Atlanta Journal-Constitution.
  5. ^ Perriello, Brad (21 January 2016). "CryoLife closes $130m On-X Technologies buyout". MassDevice. Retrieved 13 March 2023.
  6. ^ "Baxter acquires PerClot assets from CryoLife". Medical Device Network. 30 July 2021. Retrieved 14 March 2023.
  7. ^ "Jotec gehört jetzt zu US-Unternehmen". Schwarzwalder Bote. 13 October 2017. Retrieved 14 March 2023.
  8. ^ "CryoLife acquires Ascyrus Medical to expand presence in aortic market". Medical Device Network. 3 September 2020. Retrieved 13 March 2023.

Reply 3-JUL-2023

[edit]

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  00:55, 4 July 2023 (UTC)[reply]

Edit request review 3-JUL-2023

The current Infobox contains a good deal of information that is unsourced, inaccurate, or out of date.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


In January 2022, the company – which had previously been known as CryoLife – changed its name to Artivion, Inc. Artivion was founded as CryoLife in Sarasota, Florida in 1984 by Steven Anderson and Robert McNally. The company later moved from Sarasota to the Atlanta metropolitan area.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


Anderson, who had previously been the head of marketing at a pacemaker company in Texas, was appointed as the company’s president and CEO, while McNally became its vice president and chief clinical researcher.
 Unable to implement.[note 1]


n February 2008, the FDA gave CryoLife approval for a new kind of heart valve, made from human tissue
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


which was the first to remove cells from the transplant tissue as opposed to only cleaning the tissue. According to the FDA ruling, the new valve, called the CryoValve SynerGraft Pulmonary Valve, potentially had a lower risk of rejection than previous implants based on human tissue.
no Declined.[note 2]


CryoLife also used to produce a product called PerClot that removes water from blood and helps to aid the clotting process in bleeding tissues; PerClot was sold in July 2021 to Baxter International.
Clarification needed.[note 3]


Please delete the third paragraph of the present article. There is no sourcing for the entire paragraph, and most of it is simply off-topic and/or contains non-neutral language.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


In October 2017, Artivion acquired JOTEC AG, a German-based developer of medical devices for aortic and peripheral vascular diseases, for €225 million. In September 2020, the company acquired Ascyrus Medical.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


n 2000, CryoLife began offering a surgical adhesive called BioGlue used for sealing surgical lacerations under high pressure, such as in arteries. In January 2016, the company acquired On-X Life Technologies and its principal product, a mechanical heart valve called the On-X aortic valve replacement, for $130 million.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


___________

  1. ^ This portion of your request could not be implemented because the dates for these appointments have not been given.
  2. ^ These claims, while being presented as coming from the FDA, actually originated with the company, as stated in the Atlanta Journal-Constitution piece: "The Food and Drug Administration approved a new type of CryoLife heart valve it said may lower the risk of rejection, the Kennesaw-based company said Thursday."
  3. ^ It is unclear what timeframe is meant by the term "also used to produce". Please provide the dates when this product was produced.
1. This portion of your request could not be implemented because the dates for these appointments have not been given.
@Spintendo: I have broken the original sentence above into two sentences, each of which provides dates as far as sources allow. One source is primary but given that it’s being used to establish a straightforward fact (the timing of when he was appointed CEO), I think it should be okay to use here. There is no source I could find with the year McNally became chief clinical researcher, though since he was a co-founder, it seems likely it was from the co-founding in 1984. The first reference I could find with his title was from 1987. I removed any mention of the year since it’s not definite.
Here’s the new version I propose to replace the first sentence of the second paragraph (which begins with “Artivion, Inc. incorporated in 1984…”)
Anderson, who had previously been the head of marketing at a pacemaker company in Texas,[1] acted as the company’s president and CEO from its founding.[2] McNally was the chief clinical researcher.[1][3]
2. These claims, while being presented as coming from the FDA, actually originated with the company, as stated in the Atlanta Journal-Constitution piece: "The Food and Drug Administration approved a new type of CryoLife heart valve it said may lower the risk of rejection, the Kennesaw-based company said Thursday."
Thanks for pointing out that the language is a little vague in the AJC article. I’ve added two new sources to supplement the original article which clarify that the FDA that granted the approval. NBC News and a science publication confirm this. I hope this clears up any ambiguity about the language.
Here’s the new version with the additional sources included. It should replace the The third sentence in the second paragraph of the present article:
In February 2008,[4] the FDA gave CryoLife approval for a new kind of heart valve, made from human tissues, which was the first to remove cells from the transplant tissue as opposed to only cleaning the tissue.[5][6] In giving the approval, the FDA said the new valve, called the CryoValve SynerGraft Pulmonary Valve, had leds of a chance of triggering the body’s immune system, thus decreasing the risk of rejection.[6][5]
3. It is unclear what timeframe is meant by the term "also used to produce". Please provide the dates when this product was produced.
Based on User:Spintendo’s feedback, I have revised the original sentence to provide a clearer timeline of the company’s production of PerClot, including the addition of new sources that clarify the dates in question.
Here’s the new version with the additional sources included. It is meant to be the third sentence of three sentences proposed to replace the the fourth sentence in the second paragraph (which begins “Artivion's medical devices consist of…”):
In 2010, CryoLife acquired the rights to manufacture PerClot, a hemostatic agent used in surgery;[7] PerClot was later sold in 2021 to Baxter International.[8][9]
Thanks very much for your attention to this matter. W12SW77 (talk) 20:34, 2 August 2023 (UTC) W12SW77 (talk) 20:34, 2 August 2023 (UTC)[reply]

References

  1. ^ a b Zouhali-Worrall, Malika (6 July 2009). "CryoLife's near-death experience". CNN Money. Retrieved 13 March 2023.
  2. ^ "Archives". sec.gov. Retrieved 25 July 2023.
  3. ^ "Tissue frozen for transplant later". Atlanta Journal-Constitution. 12 September 1987.
  4. ^ "FDA OKs heart valve made from human tissue". Science X. 7 February 2008. Retrieved 25 July 2023.
  5. ^ a b "New heart valve may lower risk of rejection". NBC News. 7 February 2008. Retrieved 25 July 2023.
  6. ^ a b Hendrick, Bill (8 February 2008). "Kennesaw firm wins OK for heart valve: Risk of rejection may be lower for CryoLife device". Atlanta Journal-Constitution.
  7. ^ "Archives". sec.gov. Retrieved 25 July 2023.
  8. ^ Boyle, Annette (23 May 2023). "A quick two step: Artivion granted PMA for Perclot, transfers it to Baxter for $18.75M". BioWorld. Retrieved 25 July 2023.
  9. ^ "Baxter acquires PerClot assets from CryoLife". Medical Device Network. 30 July 2021. Retrieved 14 March 2023.

Reply 7-AUG-2023

[edit]

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request. Please also note that any reply messages from the COI editor should be placed underneath the edit request review section below, and not placed before it.  Spintendo  01:55, 8 August 2023 (UTC)[reply]

Edit request review 7-AUG-2023

Anderson, who had previously been the head of marketing at a pacemaker company in Texas, acted as the company's president and CEO from its founding.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


McNally was the chief clinical researcher.
no Declined.[note 1]


In February 2008, the FDA gave Cryolife approval for a new kind of heart valve...
no Declined.[note 2]


In 2010, Cryolife acquired the rights to manufacture PerClot, a hemostatic agent
no Declined.[note 3]


___________

  1. ^ "Chief clinical researcher" is a job title whose description of is not necessary to imparting the main points of the article.
  2. ^ Please provide a reference from the FDA for this claim.
  3. ^ The first wording of this proposed addition implied that this was a product developed and manufactured by the subject company. The revised proposed statement indicates that this was a product developed elsewhere and only acquired by the subject company. Products such as this, having been developed by another company and which only existed under the subject company's umbrella of manufacture for a specific time period, need not be mentioned in the article.

@Spintendo: Sorry, I previously clicked on the “reply” link instead of scrolling to the bottom of the code.

1. Here is a new sentence with the additional source from the FDA. It should replace the third sentence in the second paragraph of the present article:

In February 2008,[1] the FDA gave CryoLife approval[2] for a new kind of heart valve, made from human tissues, which was the first to remove cells from the transplant tissue as opposed to only cleaning the tissue.[3][4] In giving the approval, the FDA said the new valve, called the CryoValve SynerGraft Pulmonary Valve, had less of a chance of rejection than previous valves.[4][3]

 Done I only needed the NBC source to source all the info. The AJC source is unavailable online so is less useful anyway. STEMinfo (talk) 18:43, 14 September 2023 (UTC)[reply]

2. Reply to: The first wording of this proposed addition implied that this was a product developed and manufactured by the subject company. The revised proposed statement indicates that this was a product developed elsewhere and only acquired by the subject company. Products such as this, having been developed by another company and which only existed under the subject company's umbrella of manufacture for a specific time period, need not be mentioned in the article.

Thanks for pointing out the discrepancy between the two proposed additions. I have revised the proposed addition with added sources to provide more context around the company’s involvement in the further development of PerClot.

Here’s the new version with the additional sources included. It is meant to be the third sentence of three sentences proposed to replace the the fourth sentence in the second paragraph (which begins “Artivion's medical devices consist of…”):

In 2010, CryoLife acquired the rights to manufacture and distribute PerClot, an absorbable hemostatic powder used in surgery;[5] In 2021, the company received FDA premarket application approval of its PerClot absorbable hemostatic system,[6] which comprised PerClot granules and a delivery system for surgical use.[7] PerClot was sold in 2021 to Baxter International.[8][9]

@W12SW77: Something doesn't match. The FDA approval is dated 2023. It sounds like in 2010 they got the rights, in 2021, they sold them to Baxter with an initial payment and a conditional one. In 2023 the FDA approval comes in and then immediately in 2023 the transfer is completed to Baxter. Please confirm and revise accordingly. STEMinfo (talk) 19:32, 14 September 2023 (UTC)[reply]
@STEMinfo: Thank you for your review. Here is the clarification you requested:
In 2010, CryoLife acquired the rights to manufacture and distribute PerClot, an absorbable hemostatic powder used in surgery;[10] In 2021, the company received FDA premarket application approval of its PerClot absorbable hemostatic system,[6] which comprised PerClot granules and a delivery system for surgical use.[11] Baxter International agreed to buy PerClot from Artivion in 2021. In 2023, after final FDA approval of the product, the purchase was completed.[12][13]
Thanks for looking at this. 184.153.43.60 (talk) 14:57, 20 September 2023 (UTC)[reply]
 Done Info checks out. Resorted chronologically. STEMinfo (talk) 17:01, 21 September 2023 (UTC)[reply]

References

  1. ^ "FDA OKs heart valve made from human tissue". Science X. 7 February 2008. Retrieved 25 July 2023.
  2. ^ "510(K) Summary" (PDF). fda.gov. Retrieved 11 August 2023.
  3. ^ a b "New heart valve may lower risk of rejection". NBC News. 7 February 2008. Retrieved 25 July 2023.
  4. ^ a b Hendrick, Bill (8 February 2008). "Kennesaw firm wins OK for heart valve: Risk of rejection may be lower for CryoLife device". Atlanta Journal-Constitution.
  5. ^ "Archives". sec.gov. Retrieved 25 July 2023.
  6. ^ a b Boyle, Annette (23 May 2023). "A quick two step: Artivion granted PMA for Perclot, transfers it to Baxter for $18.75M". BioWorld. Retrieved 25 July 2023.
  7. ^ "PerClot Polysaccharide Hemostatic System - P210036". fda.gov. Retrieved 11 August 2023.
  8. ^ Boyle, Annette (23 May 2023). "A quick two step: Artivion granted PMA for Perclot, transfers it to Baxter for $18.75M". BioWorld. Retrieved 25 July 2023.
  9. ^ "Baxter acquires PerClot assets from CryoLife". Medical Device Network. 30 July 2021. Retrieved 14 March 2023.
  10. ^ "Archives". sec.gov. Retrieved 25 July 2023.
  11. ^ "PerClot Polysaccharide Hemostatic System - P210036". fda.gov. Retrieved 11 August 2023.
  12. ^ Boyle, Annette (23 May 2023). "A quick two step: Artivion granted PMA for Perclot, transfers it to Baxter for $18.75M u I". BioWorld. Retrieved 25 July 2023.
  13. ^ "Baxter acquires PerClot assets from CryoLife". Medical Device Network. 30 July 2021. Retrieved 14 March 2023.
[edit]

Hi. I work for WhiteHatWiki.com, a paid consultant to the subject of this article. I would appreciate it if an editor could please review the requested change. Thank you.

Please change the logo line in the Infobox. The current Infobox is missing any logo.

| logo =

Please replace with:

| logo = LinkedIn-Logo Corporate 300x300.jpg

Here is how the Infobox will look with the logo added: (flush right)

Artivion, Inc.
Company typePublic
NYSE: AORT
S&P 600 component
IndustryMedical devices
Founded1984
FounderSteven Anderson
Robert McNally[1][2]
HeadquartersKennesaw, Georgia, United States
Key people
Mat Packin, Chairman of the Board, President & CEO[3]
ProductsHuman tissues for transplant, surgical sealants, mechanical heart valves, stents and grafts
Revenue$298,836,000 (2022)[4]
Number of employees
1300 (2022)[4]
Websiteartivion.com

W12SW77 (talk) 15:54, 14 December 2023 (UTC)[reply]

 Done Lewcm Talk to me! 07:23, 15 December 2023 (UTC)[reply]

References

  1. ^ "Tissue frozen for transplant later". Atlanta Journal-Constitution. 12 September 1987.
  2. ^ "Steven Anderson retires". Atlanta Business Chronicle. 10 April 2015. Retrieved 13 March 2023.
  3. ^ Grayson, Katharine (14 July 2014). "Leader of Medtronic's biggest business unit leaves for CEO job". Minneapolis/St. Paul Business Journal. Retrieved 13 March 2023.
  4. ^ a b "2022 Medtech Big 100". Medical Design and Outsourcing. Retrieved 14 March 2023.
[edit]

Hello, Wikipedians. This page should be updated to include the company’s most recent logo. I work for WhiteHatWiki.com, a paid consultant to the subject of this article. I would appreciate it if an editor without a conflict of interest could please review and implement the requested change. Thanks!

1. What I think should be changed:

Please change the logo line in the Infobox:


| logo = | logo = LinkedIn-Logo Corporate 300x300.jpg

Please replace with:


| logo = Artivion Logo TM.png

Why it should be changed:

The page presently displays a logo that the company no longer uses. Adding the company’s current logo will bring the page up-to-date.

Thanks for your time on this review. W12SW77 (talk) 18:38, 14 February 2024 (UTC)[reply]

 Done ARandomName123 (talk)Ping me! 22:26, 14 February 2024 (UTC)[reply]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Artivion&oldid=1212658663"